BFS
GTBP icon

Baskin Financial Services’s GT Biopharma GTBP Stock Holding History

Baskin Financial Services’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,045
Closed -$36K – 52
2023
Q3 		$36K Hold
5,045
– – ﹤0.01% 54
2023
Q2 		$47K Hold
5,045
– – ﹤0.01% 54
2023
Q1 		$83K Hold
5,045
– – 0.01% 55
2022
Q4 		$134K Buy
+5,045
New +$252K 0.02% 53

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Baskin Financial Services's GTBP Position: Q4 2023 in Review

Baskin Financial Services sold out of GT Biopharma (GTBP) in Q4 2023, closing a stake of 5,045 shares — an estimated $36K sold.

Baskin Financial Services first reported a position in GTBP in Q4 2022 and held it in 4 quarters. The position peaked at $134K in Q4 2022. 33 funds tracked by Wall St. Rank hold GTBP as of Q4 2023.

  • Baskin Financial Services reported no remaining GT Biopharma position as of Q4 2023 after selling out during the quarter.
  • Baskin Financial Services sold 5,045 GT Biopharma shares in Q4 2023, an estimated $36K.
  • Baskin Financial Services first reported a position in GT Biopharma in Q4 2022 and held it in 4 quarters.
  • Baskin Financial Services's GT Biopharma position peaked at $134K in Q4 2022.
  • 33 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2023.

Based on Baskin Financial Services's 13F filing for Q4 2023, filed 23 Jan 2024.